Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response duration, and a median overall survival (OS) of appr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Lehmann-Che, Jacqueline, Madelaine, Isabelle, Peterlin, Pierre, Bève, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Rauzy, Odile Beyne, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Loschi, Michael, Carpentier, Antoine F., Sallman, David A., Komrokji, Rami, Walter-Petrich, Anouk, Chevret, Sylvie, Ades, Lionel, Fenaux, Pierre
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wolters Kluwer Health 2021
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099409/
https://ncbi.nlm.nih.gov/pubmed/33600210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02342
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia